Forum
Advances in basic and clinical research on hepatic ischemia-reperfusion injury
Li Shuangjiang, Xu Tingfeng, Yuan Guandou, He Songqing
Published 2023-10-08
Cite as Chin J Exp Surg, 2023, 40(10): 1925-1930. DOI: 10.3760/cma.j.cn421213-20230207-01048
Abstract
Ischemia-reperfusion injury (IRI) is a phenomenon in which the damage to an organ is further aggravated or even irreversible after restoring blood flow on the basis of ischemia. Clinically, IRI is common in substantial organs such as liver, brain and kidney. Among them, hepatic ischemia-reperfusion injury (HIRI) is one of the main causes of hepatic impairment and even liver failure after partial hepatectomy and liver transplantation, and it is closely related to the prognosis of the patients. The occurrence and development of HIRI involves a variety of mechanisms, and the accumulation of oxygen free radicals and inflammation are the main pathophysiological processes. In addition, HIRI is closely related to the "double-edged sword" complement. This article mainly discusses the basic and clinical research progress of HIRI, and provides theoretical and practical references for the prevention and treatment of HIRI.
Key words:
Ischemia-reperfusion injury; Liver disease; Hepatectomy; Liver transplantation; Complement
Contributor Information
Li Shuangjiang
Division of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical UniversityNanning 530021, China
Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education Nanning 530021, China
Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Nanning 530021, China
Xu Tingfeng
Division of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical UniversityNanning 530021, China
Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education Nanning 530021, China
Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Nanning 530021, China
Yuan Guandou
Division of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical UniversityNanning 530021, China
Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education Nanning 530021, China
Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Nanning 530021, China
He Songqing
Division of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical UniversityNanning 530021, China
Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education Nanning 530021, China
Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Nanning 530021, China
